Dementia and Alzheimer Disease

Gregory Hawryluk, MD, PhD, a neurosurgeon at Cleveland Clinic, spoke on the development and clinical impact of new global guidelines for penetrating traumatic brain injury.

Neurology News Network for the week ending November 1, 2025. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Rebecca Edelmayer, PhD. [LISTEN TIME: 14 minutes]

The FDA accepts Lantheus' MK-6240 application, a promising PET imaging agent for Alzheimer disease, enhancing diagnosis and treatment strategies.

A recent study highlights the increased mortality risk linked to benzodiazepine and antipsychotic use in hospice patients with dementia, urging new prescribing guidelines.

Neurology News Network for the week ending October 25, 2025. [WATCH TIME: 4 minutes]

A recent meta-analysis reveals frontotemporal dementia's incidence and prevalence, highlighting its significance in clinical research and treatment advancements.

The FDA has granted fast track designation to Eisai’s etalanetug, an anti-tau antibody targeting tau pathology in Alzheimer's disease.

Beth McQuiston, MD, neurologist and medical director in Abbott’s diagnostics business, discussed the clinical value of Abbott’s FDA-cleared i-STAT TBI test as it was named to TIME’S 2025 Best Inventions List.

Neurology News Network. for the week ending October 18, 2025. [WATCH TIME: 4 minutes]

Roche's Elecsys pTau181 test receives FDA clearance, revolutionizing Alzheimer diagnosis in primary care with a minimally invasive blood test.

Neurology News Network. for the week ending October 11, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

Neflamapimod treatment led to slowing of clinical worsening, as assessed by Clinical Dementia Rating-Sum of Boxes, when drug concentrations were achieved.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Bristol Myers Squibb's BMS-986446 receives FDA fast track designation, targeting tau protein to combat early-stage Alzheimer's disease in ongoing trials.

Eli Lilly's donanemab gains EU approval, offering hope for early Alzheimer's treatment with a new dosing regimen that reduces side effects.

Xu Li, PhD, a research associate in the F.M. Kirby Research Center for Functional Brain Imaging at Kennedy Krieger Institute, provided commentary on a promising, recently published study using QSM MRI to detect cognitive changes in Alzheimer disease.

The vice president of scientific engagement at the Alzheimer’s Association provided clinical insights on the most major considerations and precautions clinicians should have about diagnostic and commercially available tests for suspected Alzheimer disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.

The vice president of scientific engagement at the Alzheimer’s Association discussed the organization’s recently published first guidelines on blood-based biomarkers, highlighting accuracy, clinical use, and patient considerations.

Ionis reveals promising trial results for zilganersen, a potential first treatment for Alexander disease, aiming to transform patient care.

Here's some of what is coming soon to NeurologyLive® this week.

The vice chair of neurology at West Virginia University outlined key challenges in academic neurology and reflected on the evolving responsibilities of vice chairs in supporting departmental growth and leadership. [WATCH TIME: 3 minutes]